Article thumbnail

The Effect of Intravitreal Bevacizumab in Patients with Acute Central Serous Chorioretinopathy

By Ji Won Lim, Su Jeong Ryu and Min Cheol Shin
Topics: Original Article
Publisher: The Korean Ophthalmological Society
OAI identifier: oai:pubmedcentral.nih.gov:2882078
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol
  2. (2005). Acute central serous chorioretinopathy and fundus autofluorescence. Retina
  3. Central serous chorioretinopathy and indocyanine green angiography.
  4. Central serous chorioretinopathy.
  5. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).
  6. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.
  7. Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy.
  8. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
  9. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update.
  10. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
  11. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.
  12. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
  13. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography.
  14. Pathogenesis of disciform detachment of neuroepithelium: II. Idiopathic central serous choroidopathy.
  15. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.
  16. Penetration of bevacizumab through the retina after intravitreal injection in the monkey.
  17. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy.